Leveraging human microbiomes for disease prediction and treatment

Trends Pharmacol Sci. 2025 Jan;46(1):32-44. doi: 10.1016/j.tips.2024.11.007. Epub 2024 Dec 27.

Abstract

The human microbiome consists of diverse microorganisms that inhabit various body sites. As these microbes are increasingly recognized as key determinants of health, there is significant interest in leveraging individual microbiome profiles for early disease detection, prevention, and drug efficacy prediction. However, the complexity of microbiome data, coupled with conflicting study outcomes, has hindered its integration into clinical practice. This challenge is partially due to demographic and technological biases that impede the development of reliable disease classifiers. Here, we examine recent advances in 16S rRNA and shotgun-metagenomics sequencing, along with bioinformatics tools designed to enhance microbiome data integration for precision diagnostics and personalized treatments. We also highlight progress in microbiome-based therapies and address the challenges of establishing causality to ensure robust diagnostics and effective treatments for complex diseases.

Keywords: C. difficile infection; clinical metagenomics; inflammatory bowel disease; irritable bowel syndrome; microbiome; pan-microbiome profiling.

MeSH terms

  • Animals
  • Computational Biology
  • Humans
  • Metagenomics
  • Microbiota*
  • Precision Medicine / methods
  • RNA, Ribosomal, 16S / genetics

Substances

  • RNA, Ribosomal, 16S